Nagendrakumar Singanallur Balasubramanian

Dr. Nagendrakumar Singanallur Balasubramanian

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2008 in Journal of Virological Methods
Verified
Journal Article
Closed access
MMMadhanmohan Muthukrishnan
Madhanmohan Muthukrishnan
NBNagendrakumar Singanallur Balasubramanian
Nagendrakumar Singanallur Balasubramanian
KRKumar Ralla
Kumar Ralla
SVSrinivasan A. Villuppanoor
Srinivasan A. Villuppanoor

11 December 2013 in Transboundary and Emerging Diseases
Verified
Journal Article
Closed access
PDF file
WVWilna Vosloo
Wilna Vosloo
JMJ. Morris
J. Morris
ADA. Davis
A. Davis
MGM. Giles
M. Giles
JWJ. Wang
J. Wang
NBNagendrakumar Singanallur Balasubramanian
Nagendrakumar Singanallur Balasubramanian

1 January 2015 in Vaccine
Verified
Journal Article
Closed access
JHJacquelyn Horsington
Jacquelyn Horsington
Zhidong ZhangZhidong Zhang
Zhidong Zhang
HBHilary Bittner
Hilary Bittner
KHKate Hole
Kate Hole
NBNagendrakumar Singanallur Balasubramanian
Nagendrakumar Singanallur Balasubramanian
WVWilna Vosloo
Wilna Vosloo

1 August 2010 in Clinical and Vaccine Immunology
Verified
Journal Article
Closed access
RSRajalakshmi Shanmugham
Rajalakshmi Shanmugham
NTNagarajan Thirumeni
Nagarajan Thirumeni
VRVaraprasada Sankarashetty Rao
Varaprasada Sankarashetty Rao
VPVidyasagar Pitta
Vidyasagar Pitta
SKSaranyarevathy Kasthuri
Saranyarevathy Kasthuri
SASrinivasan Villuppanoor Alwar
Srinivasan Villuppanoor Alwar
Quantification of hepatitis B surface antigen (HBsAg) or relative in vitro potency in the final vaccines is a prerequisite for hepatitis B vaccine batch release. The commercial kit for automated analysis (AxSYM) is expensive, and an alternative is required for the estimation of HBsAg in hepatitis B vaccines. Mouse monoclonal antibodies (MAbs) specific for HBsAg were developed and characterized. One of the monoclonal antibodies (HBs06) was used in development of an immunocapture ELISA (IC-ELISA) as an unlabeled capture antibody and biotin-labeled detection antibody. The IC-ELISA was standardized and validated using experimental hepatitis B vaccine batches with various HBsAg concentrations per dose and commercial vaccines. The vaccine was treated with an alkaline solubilizer to desorb the HBsAg from Algel-adjuvanted vaccines before testing, and the sensitivity of the test was 5 ng/ml. A good correlation could be observed between the HBsAg estimates derived by both formats, except for the higher HBsAg concentration range, where the IC-ELISA format could estimate closer to the actual values than AxSYM. There was a significant correlation between the estimated relative potencies of the two methods. There was lack of correlation between the in vivo potency and the relative in vitro potency. However, the estimates of IC-ELISA were comparable to the in vivo values when compared with the estimates of AxSYM. The IC-ELISA can therefore be considered to be a reliable test for deriving in vitro relative potency and antigen concentration in vaccine batches for batch control and release.

1 August 2010 in Clinical and Vaccine Immunology
Verified
Journal Article
Closed access
SNSridevi V. Nimmagadda
Sridevi V. Nimmagadda
SAShukra M. Aavula
Shukra M. Aavula
NBNeelakantam Biradhar
Neelakantam Biradhar
VRVaraprasada Sankarasetty Rao
Varaprasada Sankarasetty Rao
RSRajalakshmi Shanmugham
Rajalakshmi Shanmugham
SASrinivasan Villuppanoor Alwar
Srinivasan Villuppanoor Alwar
The potency of rabies vaccines, determined using the NIH mouse protection test, can be directly correlated to the amount of rabies virus glycoprotein (RV GP) present in the vaccine. In an effort to develop a simple and sensitive enzyme-linked immunosorbent assay (ELISA) using recombinant diabody for quantification of RV GP, the variable heavy (V H ) and light chain (V L ) domains of an RV GP-specific human monoclonal antibody (MAb) secreted by a human × mouse heterohybridoma (human MAb R16E5) was amplified, linked using splicing by overlap extension PCR (SOE PCR), and expressed as a recombinant diabody (D06) in the pET28a bacterial expression system. The diabody D06 was purified by immobilized metal affinity chromatography on a nickel-nitrilotriacetic acid (NTA) agarose column and characterized. The purified diabody was used in combination with a well-characterized RV GP-specific mouse MAb, M5B4, to develop an immunocapture ELISA (IC-ELISA) for the quantification of RV GP in human rabies vaccine preparations. The maximum detection limit of the IC-ELISA using the M5B4-D06 combination was up to 31.25 ng/ml of RV GP. The specificity of the diabody was established by its nonreactivity toward other human viral antigens as determined by ELISA and toward RV GP as determined by immunoblot transfer assay and competitive ELISA with the parent human MAb R16E5 and MAb M5B4. The adjusted r 2 value obtained by the regression through the origin model was 0.902, and the equation for predicted potency values for M5B4-D06-based IC-ELISA and MAb M5B4 IC-ELISA were 0.5651 x and 0.8044 x , respectively, where x is the estimate of RV GP from the IC-ELISA in micrograms. Analysis of variance (ANOVA) results showed the estimates of the two methods differed significantly ( P < 0.001), while the predicted potencies by the two tests did not differ significantly ( P > 0.05). The IC-ELISA can be readily adapted to measure the RV GP content in purified antigen, and a vaccine can be formulated based on the estimated GP.

31 October 2022 in Viruses
Verified
Journal Article
Open access
PDF file
AMAlexander McAuley
Alexander McAuley
PVPetrus Jansen Van Vuren
Petrus Jansen Van Vuren
MRMuzaffar Ur Rehman
Muzaffar Ur Rehman
FAFaheem
Faheem
SGSarah Goldie
Sarah Goldie
SVSeshadri S Vasan
Seshadri S Vasan
The repurposing of licenced drugs for use against COVID-19 is one of the most rapid ways to develop new and alternative therapeutic options to manage the ongoing pandemic. Given circa 7817 licenced compounds available from Compounds Australia that can be screened, this paper demonstrates the utility of commercially available ex vivo/3D airway and alveolar tissue models. These models are a closer representation of in vivo studies than in vitro models, but retain the benefits of rapid in vitro screening for drug efficacy. We demonstrate that several existing drugs appear to show anti-SARS-CoV-2 activity against both SARS-CoV-2 Delta and Omicron Variants of Concern in the airway model. In particular, fluvoxamine, as well as aprepitant, everolimus, and sirolimus, has virus reduction efficacy comparable to the current standard of care (remdesivir, molnupiravir, nirmatrelvir). Whilst these results are encouraging, further testing and efficacy studies are required before clinical use can be considered.